LORIUM · 10 mg LYOPHILISED VIALTirzepatide
GLP-1 T is an advanced, next-generation peptide engineered for optimal metabolic refinement, precision weight management, and appetite control. By co-activating dual incretin pathways, it safely synchronizes metabolic biomarkers to support sustainable body composition and peak cellular vitality.
Researched effects
Effects observed in the cited literature. Individual results are not guaranteed. Statements have not been evaluated by the FDA.
Weight Optimization
Up to 22.5% reduction in total body weight.
Glycemic Control
Reduces HbA1c by 1.87%–2.58%; up to 62.4% achieve normoglycemia.
Cardiometabolic Care
Lowers blood pressure, triglycerides, and inflammation markers.
Enhanced Safety Profile
Significantly fewer hypoglycemic episodes than traditional insulin.
Dual Action
Co-agonist targeting both GIP & GLP-1 receptors.
Smart Satiety
Delays gastric emptying and reduces neural food cravings.
Premium Tolerability
Minimal GI side effects; ultra-low discontinuation rates (4.3%–7.1%).
Specifications
Clinical references
- Nauck, M.A., et al. (2022). Cardiovascular Diabetology, 21(1), 169. DOI: 10.1186/s12933-022-01604-7
- Willard, F.S., et al. (2020). JCI Insight, 5(17), e140532. DOI: 10.1172/jci.insight.140532
- Frías, J.P., et al. (2021). NEJM, 385(6), 503-515. DOI: 10.1056/NEJMoa2107519
- Jastreboff, A.M., et al. (2022). NEJM, 387(3), 205-216. DOI: 10.1056/NEJMoa2206038
- Yang, J., et al. (2024). Frontiers in Pharmacology, 15, 1453825. DOI: 10.3389/fphar.2024.1453825.
More in Metabolic
AOD-9604
A structurally modified fragment of human growth hormone designed to target adipose tissue metabolism and enhance fat breakdown.
Retatrutide
A breakthrough triple-receptor agonist targeting GLP-1, GIP, and glucagon pathways for notable fat oxidation and comprehensive metabolic reprogramming.
Semaglutide
A long-acting GLP-1 receptor agonist with 94% homology to natural human GLP-1, delivering sustained metabolic control, appetite suppression, and multi-organ protection.